Radioimmunotherapy (RIT) is a type of targeted cancer therapy that combines the specificity of monoclonal antibodies with the destructive power of radiation. The treatment involves attaching radioactive isotopes to monoclonal antibodies, which are specialized proteins that can recognize and bind to specific antigens found on the surface of cancer cells.
Market Analysis and Insights: Global Radioimmunotherapy Market
The global Radioimmunotherapy market is projected to grow from US$ 1707.6 million in 2024 to US$ 4477.8 million by 2030, at a Compound Annual Growth Rate (CAGR) of 17.4% during the forecast period.
Global 5 largest Companies of Radioimmunotherapy are Novartis, Bayer, China Isotope & Radiation, Curium Pharmaceuticals and Aurobindo Pharma, which make up over 99%. Among them, Novartis is the leader with about 85% market share. North America is the largest market, with a share about 51%, followed by Europe and Asia-Pacific, with the share about 33% and 14%. In terms of product type, Beta-emitting occupy the largest share of the total market, about 85%. And in terms of product Application, the largest application is Solid Tumor, followed by Non Hodgkin Lymphoma.
Report Covers:
This report presents an overview of global market for Radioimmunotherapy market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Radioimmunotherapy, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Radioimmunotherapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Radioimmunotherapy revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Radioimmunotherapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Radioimmunotherapy revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation
By Company
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals
Segment by Type
Beta-emitting
Targeted Alpha Therapy
Segment by Application
Solid Tumor
Non Hodgkin Lymphoma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Radioimmunotherapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Radioimmunotherapy companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Radioimmunotherapy revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Radioimmunotherapy Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Beta-emitting
1.2.3 Targeted Alpha Therapy
1.3 Market by Application
1.3.1 Global Radioimmunotherapy Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Solid Tumor
1.3.3 Non Hodgkin Lymphoma
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Radioimmunotherapy Market Perspective (2019-2030)
2.2 Global Radioimmunotherapy Growth Trends by Region
2.2.1 Radioimmunotherapy Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Radioimmunotherapy Historic Market Size by Region (2019-2024)
2.2.3 Radioimmunotherapy Forecasted Market Size by Region (2025-2030)
2.3 Radioimmunotherapy Market Dynamics
2.3.1 Radioimmunotherapy Industry Trends
2.3.2 Radioimmunotherapy Market Drivers
2.3.3 Radioimmunotherapy Market Challenges
2.3.4 Radioimmunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Radioimmunotherapy by Players
3.1.1 Global Radioimmunotherapy Revenue by Players (2019-2024)
3.1.2 Global Radioimmunotherapy Revenue Market Share by Players (2019-2024)
3.2 Global Radioimmunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Radioimmunotherapy, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Radioimmunotherapy Market Concentration Ratio
3.4.1 Global Radioimmunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radioimmunotherapy Revenue in 2023
3.5 Global Key Players of Radioimmunotherapy Head office and Area Served
3.6 Global Key Players of Radioimmunotherapy, Product and Application
3.7 Global Key Players of Radioimmunotherapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Radioimmunotherapy Breakdown Data by Type
4.1 Global Radioimmunotherapy Historic Market Size by Type (2019-2024)
4.2 Global Radioimmunotherapy Forecasted Market Size by Type (2025-2030)
5 Radioimmunotherapy Breakdown Data by Application
5.1 Global Radioimmunotherapy Historic Market Size by Application (2019-2024)
5.2 Global Radioimmunotherapy Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Radioimmunotherapy Market Size (2019-2030)
6.2 North America Radioimmunotherapy Market Size by Type
6.2.1 North America Radioimmunotherapy Market Size by Type (2019-2024)
6.2.2 North America Radioimmunotherapy Market Size by Type (2025-2030)
6.2.3 North America Radioimmunotherapy Market Share by Type (2019-2030)
6.3 North America Radioimmunotherapy Market Size by Application
6.3.1 North America Radioimmunotherapy Market Size by Application (2019-2024)
6.3.2 North America Radioimmunotherapy Market Size by Application (2025-2030)
6.3.3 North America Radioimmunotherapy Market Share by Application (2019-2030)
6.4 North America Radioimmunotherapy Market Size by Country
6.4.1 North America Radioimmunotherapy Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Radioimmunotherapy Market Size by Country (2019-2024)
6.4.3 North America Radioimmunotherapy Market Size by Country (2025-2030)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Radioimmunotherapy Market Size (2019-2030)
7.2 Europe Radioimmunotherapy Market Size by Type
7.2.1 Europe Radioimmunotherapy Market Size by Type (2019-2024)
7.2.2 Europe Radioimmunotherapy Market Size by Type (2025-2030)
7.2.3 Europe Radioimmunotherapy Market Share by Type (2019-2030)
7.3 Europe Radioimmunotherapy Market Size by Application
7.3.1 Europe Radioimmunotherapy Market Size by Application (2019-2024)
7.3.2 Europe Radioimmunotherapy Market Size by Application (2025-2030)
7.3.3 Europe Radioimmunotherapy Market Share by Application (2019-2030)
7.4 Europe Radioimmunotherapy Market Size by Country
7.4.1 Europe Radioimmunotherapy Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Radioimmunotherapy Market Size by Country (2019-2024)
7.4.3 Europe Radioimmunotherapy Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Radioimmunotherapy Market Size (2019-2030)
8.2 China Radioimmunotherapy Market Size by Type
8.2.1 China Radioimmunotherapy Market Size by Type (2019-2024)
8.2.2 China Radioimmunotherapy Market Size by Type (2025-2030)
8.2.3 China Radioimmunotherapy Market Share by Type (2019-2030)
8.3 China Radioimmunotherapy Market Size by Application
8.3.1 China Radioimmunotherapy Market Size by Application (2019-2024)
8.3.2 China Radioimmunotherapy Market Size by Application (2025-2030)
8.3.3 China Radioimmunotherapy Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Radioimmunotherapy Market Size (2019-2030)
9.2 Asia Radioimmunotherapy Market Size by Type
9.2.1 Asia Radioimmunotherapy Market Size by Type (2019-2024)
9.2.2 Asia Radioimmunotherapy Market Size by Type (2025-2030)
9.2.3 Asia Radioimmunotherapy Market Share by Type (2019-2030)
9.3 Asia Radioimmunotherapy Market Size by Application
9.3.1 Asia Radioimmunotherapy Market Size by Application (2019-2024)
9.3.2 Asia Radioimmunotherapy Market Size by Application (2025-2030)
9.3.3 Asia Radioimmunotherapy Market Share by Application (2019-2030)
9.4 Asia Radioimmunotherapy Market Size by Region
9.4.1 Asia Radioimmunotherapy Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Radioimmunotherapy Market Size by Region (2019-2024)
9.4.3 Asia Radioimmunotherapy Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Radioimmunotherapy Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Type
10.2.1 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Radioimmunotherapy Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Application
10.3.1 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Radioimmunotherapy Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Country
10.4.1 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Radioimmunotherapy Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Details
11.1.2 Bayer Business Overview
11.1.3 Bayer Radioimmunotherapy Introduction
11.1.4 Bayer Revenue in Radioimmunotherapy Business (2019-2024)
11.1.5 Bayer Recent Developments
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Radioimmunotherapy Introduction
11.2.4 Novartis Revenue in Radioimmunotherapy Business (2019-2024)
11.2.5 Novartis Recent Developments
11.3 Lantheus
11.3.1 Lantheus Company Details
11.3.2 Lantheus Business Overview
11.3.3 Lantheus Radioimmunotherapy Introduction
11.3.4 Lantheus Revenue in Radioimmunotherapy Business (2019-2024)
11.3.5 Lantheus Recent Developments
11.4 Aurobindo Pharma
11.4.1 Aurobindo Pharma Company Details
11.4.2 Aurobindo Pharma Business Overview
11.4.3 Aurobindo Pharma Radioimmunotherapy Introduction
11.4.4 Aurobindo Pharma Revenue in Radioimmunotherapy Business (2019-2024)
11.4.5 Aurobindo Pharma Recent Developments
11.5 Mundipharma
11.5.1 Mundipharma Company Details
11.5.2 Mundipharma Business Overview
11.5.3 Mundipharma Radioimmunotherapy Introduction
11.5.4 Mundipharma Revenue in Radioimmunotherapy Business (2019-2024)
11.5.5 Mundipharma Recent Developments
11.6 China Isotope & Radiation
11.6.1 China Isotope & Radiation Company Details
11.6.2 China Isotope & Radiation Business Overview
11.6.3 China Isotope & Radiation Radioimmunotherapy Introduction
11.6.4 China Isotope & Radiation Revenue in Radioimmunotherapy Business (2019-2024)
11.6.5 China Isotope & Radiation Recent Developments
11.7 Curium Pharmaceuticals
11.7.1 Curium Pharmaceuticals Company Details
11.7.2 Curium Pharmaceuticals Business Overview
11.7.3 Curium Pharmaceuticals Radioimmunotherapy Introduction
11.7.4 Curium Pharmaceuticals Revenue in Radioimmunotherapy Business (2019-2024)
11.7.5 Curium Pharmaceuticals Recent Developments
11.8 Gilead Sciences
11.8.1 Gilead Sciences Company Details
11.8.2 Gilead Sciences Business Overview
11.8.3 Gilead Sciences Radioimmunotherapy Introduction
11.8.4 Gilead Sciences Revenue in Radioimmunotherapy Business (2019-2024)
11.8.5 Gilead Sciences Recent Developments
11.9 Clarity Pharmaceuticals
11.9.1 Clarity Pharmaceuticals Company Details
11.9.2 Clarity Pharmaceuticals Business Overview
11.9.3 Clarity Pharmaceuticals Radioimmunotherapy Introduction
11.9.4 Clarity Pharmaceuticals Revenue in Radioimmunotherapy Business (2019-2024)
11.9.5 Clarity Pharmaceuticals Recent Developments
11.10 Curasight
11.10.1 Curasight Company Details
11.10.2 Curasight Business Overview
11.10.3 Curasight Radioimmunotherapy Introduction
11.10.4 Curasight Revenue in Radioimmunotherapy Business (2019-2024)
11.10.5 Curasight Recent Developments
11.11 Nordic Nanovector
11.11.1 Nordic Nanovector Company Details
11.11.2 Nordic Nanovector Business Overview
11.11.3 Nordic Nanovector Radioimmunotherapy Introduction
11.11.4 Nordic Nanovector Revenue in Radioimmunotherapy Business (2019-2024)
11.11.5 Nordic Nanovector Recent Developments
11.12 Philogen
11.12.1 Philogen Company Details
11.12.2 Philogen Business Overview
11.12.3 Philogen Radioimmunotherapy Introduction
11.12.4 Philogen Revenue in Radioimmunotherapy Business (2019-2024)
11.12.5 Philogen Recent Developments
11.13 RadioMedix
11.13.1 RadioMedix Company Details
11.13.2 RadioMedix Business Overview
11.13.3 RadioMedix Radioimmunotherapy Introduction
11.13.4 RadioMedix Revenue in Radioimmunotherapy Business (2019-2024)
11.13.5 RadioMedix Recent Developments
11.14 Telix Pharmaceuticals
11.14.1 Telix Pharmaceuticals Company Details
11.14.2 Telix Pharmaceuticals Business Overview
11.14.3 Telix Pharmaceuticals Radioimmunotherapy Introduction
11.14.4 Telix Pharmaceuticals Revenue in Radioimmunotherapy Business (2019-2024)
11.14.5 Telix Pharmaceuticals Recent Developments
11.15 Orano Med
11.15.1 Orano Med Company Details
11.15.2 Orano Med Business Overview
11.15.3 Orano Med Radioimmunotherapy Introduction
11.15.4 Orano Med Revenue in Radioimmunotherapy Business (2019-2024)
11.15.5 Orano Med Recent Developments
11.16 Actinium Pharmaceuticals
11.16.1 Actinium Pharmaceuticals Company Details
11.16.2 Actinium Pharmaceuticals Business Overview
11.16.3 Actinium Pharmaceuticals Radioimmunotherapy Introduction
11.16.4 Actinium Pharmaceuticals Revenue in Radioimmunotherapy Business (2019-2024)
11.16.5 Actinium Pharmaceuticals Recent Developments
11.17 Y-mAbs Therapeutics
11.17.1 Y-mAbs Therapeutics Company Details
11.17.2 Y-mAbs Therapeutics Business Overview
11.17.3 Y-mAbs Therapeutics Radioimmunotherapy Introduction
11.17.4 Y-mAbs Therapeutics Revenue in Radioimmunotherapy Business (2019-2024)
11.17.5 Y-mAbs Therapeutics Recent Developments
11.18 Fusion Pharmaceuticals
11.18.1 Fusion Pharmaceuticals Company Details
11.18.2 Fusion Pharmaceuticals Business Overview
11.18.3 Fusion Pharmaceuticals Radioimmunotherapy Introduction
11.18.4 Fusion Pharmaceuticals Revenue in Radioimmunotherapy Business (2019-2024)
11.18.5 Fusion Pharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Bayer
Novartis
Lantheus
Aurobindo Pharma
Mundipharma
China Isotope & Radiation
Curium Pharmaceuticals
Gilead Sciences
Clarity Pharmaceuticals
Curasight
Nordic Nanovector
Philogen
RadioMedix
Telix Pharmaceuticals
Orano Med
Actinium Pharmaceuticals
Y-mAbs Therapeutics
Fusion Pharmaceuticals
听
听
*If Applicable.